A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+,...

Journal of Thoracic Oncology 2018 / 08 Vol. 13; Iss. 8

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Lisberg, A., Cummings, A., Goldman, J.W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., Wolf, B., Jones, B., Madrigal, J., Horton, J., Spiegel, M., Carroll, J
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
13
Language:
english
Journal:
Journal of Thoracic Oncology
DOI:
10.1016/j.jtho.2018.03.035
Date:
August, 2018
File:
PDF, 389 KB
english, 2018
Conversion to is in progress
Conversion to is failed